Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Dec 10, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – National Institute of General Medical Sciences Director Jeremy Berg will step down from his position to take on the role of associate vice chancellor for strategy and planning in the health sciences at the University of Pittsburgh. Berg will leave the NIGMS leadership position in June, 2011. He said in a statement from the National Institutes of Health that he decided to leave his position and take on the job in Pittsburgh because his wife, a breast cancer researcher, was offered a position at the same university.

WaferGen has named Timothy Triche to serve on its scientific advisory board. Triche is a professor of pathology and pediatrics at the University of Southern California Keck School of Medicine and is director of the Center for Personalized Medicine at Children's Hospital Los Angeles. Triche recently was section chief and head of Molecular Diagnostics in the Laboratory of Pathology at the National Cancer Institute and currently is a standing member of NCI's advisory committees for clinical and basic cancer biology research.

CombiMatrix has hired Tim Flores to be director of sales for CombiMatrix Diagnostics. Flores recently was director of corporate accounts at Ventana Medical Systems and he spent 16 years at Abbott Diagnostics in sales, marketing, and management.

Selventa has promoted David de Graaf to the CEO position from his current title of chief scientific officer. De Graaf has been CSO since June. Before joining the company he was VP of Biotherapeutics and Integrative Biology at Boehringer Ingelheim. He has formerly worked at the Whitehead/MIT Center for Genome Research, at Pfizer, and at AstraZeneca. Selventa was formerly called Genstruct.

RainDance Technologies has tapped Mark Dronsfield to be director of sales for Europe. Dronsfield formerly worked at Cell Biosciences where he was European sales director, and he spent time in leadership positions at Solexa, now part of Illumina, Affymetrix, and Applied Biosystems, now part of Life Technologies.

Vermillion has reappointed company President Gail Page, as well as John Hamilton and William Wallen to continue serving as company directors. The firm had asked Page to step down as President and CEO to conserve funds due to the firm's Chapter 11 bankruptcy status, but it reappointed her as CEO in February, 2010. Hamilton formerly was VP and CFO of Depomed, and Wallen was senior VP and CSO at Idexx Laboratories.

Myriad Genetics' stakeholders have elected company CEO and President Peter Meldrum, and former president and CEO at Roche Molecular Systems Heiner Dreismann, to serve as company directors for three-year terms that will expire in 2013.

Uwe Neue, who spent more than three decades at Waters, died on December 3 after a brief illness. Neue was director of External Research at Waters and was appointed a Waters Corporate Fellow in 2008.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.